Navigation Links
Kymos, a Catalan Company, Signs a Collaboration Agreement With the Pharmaceutical Group Ipsen
Date:12/14/2011

BARCELONA, Spain, December 14, 2011 /PRNewswire/ --

The Contract Research Organization Kymos Pharma Services -specialised in analysis for the pharmaceutical, fine chemicals, biotechnological, veterinary, cosmetic and nutraceuticals sectors- has signed an agreement with the French multinational group Ipsen to take in a team of eight scientists from Ipsen R&D Centre in Sant Feliu de Llobregat (Barcelona).

For Kymos -with headquarters in Barcelona Science Park (PCB) and celebrating its 10th anniversary this year- this agreement allows the creation of an innovative area of R&D services in the field of bio molecules and biosimilars. Kymos will carry out this activity in a new immunology laboratory that will be opened in the PCB in early January 2012, conducting regulatory development projects for biotech companies.

"This new alliance consolidates the company's growth plan. The agreement also speeds up our international expansion plans, thus our company will be the only Spanish CRO and one of the few European ones that will be able to offer comprehensive services for biotech companies according to Good Laboratory Practices and Good Manufacturing Practices," says Joan Puig, strategic general manager of Kymos.  

About KymosPharma Services

Kymos Pharma Services is a CRO located in the PCB that was created in 2001 by a group of professionals with over 10 years of experience in R&D of pharmaceutical companies. The company is focused on comprehensive analytical development studies for pharmaceutical and related sectors, as well as on bioanalysis of preclinical and clinical studies of small molecules. At present, its financial turnover exceeds 2.5 million Euros, with a staff of 35 professionals and direct activities in Portugal and Italy. The company has over 80 clients, including the main Spanish pharmaceutical companies and clients from several countries such as France, Great Britain and Switzerland.

About Ipsen

Ipsen is a French biotechnology multinational group with sales of 1,100 million Euros that is listed on the Euronext stockmarket of Paris. It has 4,500 employees worldwide with offices in 50 countries and products sold in over 100.  As a leader in the biotech sector, Ipsen assigns 20% of its profits to R+D focused on the development of peptides and proteins in the therapeutic areas of neurology, endocrinology, oncology and haematology.  



 


'/>"/>
SOURCE Kymos Pharma Services
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
2. IPC The Hospitalist Company, Inc. to Report Third Quarter 2009 Results
3. Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy
4. IPC The Hospitalist Company, Inc. to Present at the 2009 Annual Credit Suisse Health Care Conference
5. Providence Service Corporation to Present at the Sidoti & Company, LLC Micro Cap Conference on Monday, January 11th and at the CJS Securities New Ideas for the New Year Conference on Thursday, January 14th
6. RoundTable Healthcare Partners Portfolio Company, Aspen Surgical Products, Inc., Acquires Bard-Parker™ Surgical Blades and Scalpels Business
7. QuantaLife, a New Life Science Tool Company, Receives NIH Grant
8. RoundTable Healthcare Partners Portfolio Company, Argon Medical Devices, Inc., Acquires Critical Care and Extended Dwell Catheter Product Platforms From BD
9. IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results
10. Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company
11. LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):